Navigation Links
Meditope Biosciences Appoints Prominent Scientific Advisory Board
Date:1/14/2014

PASADENA, Calif., Jan. 14, 2014 /PRNewswire/ -- Meditope Biosciences, Inc., a biotechnology company developing antibody-based products, today announced the appointment of inaugural members of its newly-formed scientific advisory board.  The board will leverage its extensive experience in protein engineering to advise the company to help advance its proprietary monoclonal antibody (mAb) technology platform for the development of novel antibody-drug conjugates.

"We are very proud to appoint these prominent members of science and industry, as we work to quickly and efficiently apply our exciting new technology to a spectrum of drug development programs," said Stephanie Hsieh, Meditope's president and chief executive officer.  "Recently, we have made significant progress to establish our technology platform and initiate key studies that will inform our cancer drug development programs.  The strategic input from these experienced advisors will be key as we seek out meaningful development partnerships and maximize opportunities to deploy our best in class antibody-drug conjugate technology."

Members of the scientific advisory board include:

  • Peter B. Dervan, PhD, Bren Professor of Chemistry at the California Institute of Technology.  He is also a member of the National Academy of Sciences, the Institute of Medicine, the American Academy of Arts & Sciences, the American Philosophical Society, and a Foreign Member of both the French and German Academies of Science.  Dr. Dervan was awarded the National Medal of Science in 2006.  He has served on numerous Scientific Advisory Boards, including that of Gilead Sciences, Inc.  Dr. Dervan is recognized for creating a new field of bioorganic chemistry directed towards understanding the chemical principles for the sequence specific recognition of DNA.
  • Iqbal S. Grewal, PhD, DSc, FRCPath, Chief Scientific Officer and a director of ImmunGene, Inc.  Prior to joining ImmunGene, Dr. Grewal served as Vice President of Preclinical Therapeutics at Seattle Genetics, where he managed preclinical translational research functions for development of monoclonal antibodies and antibody-drug conjugates as therapeutics in the areas of oncology and autoimmunity.  His career also includes discovery research and preclinical development of biologics at Genentech, as well as various research positions at Yale University School of Medicine and the University of California, Los Angeles.  He is a fellow of the Royal College of Pathologists, London and member of several distinguished societies. He has extensive experience in the discovery and development of innovative protein-based biotherapeutics in many disease areas.
  • Arthur D. Riggs, PhD, Director Emeritus and current Chair of the Diabetes Research Department of the Beckman Research Institute at City of Hope. Dr. Riggs was the founding dean of the City of Hope's graduate school.  He is also a Member of the National Academy of Sciences. Previously, Dr. Riggs worked with Genentech to express the first artificial genes, for somatostatin and insulin, in bacteria.  His work helped form the bedrock of the modern biotechnology industry, enabling the large-scale manufacture of protein drugs, like synthetic human insulin, and developing recombinant DNA techniques that are the basis for creating therapeutic monoclonal antibodies.
  • John C. Williams, PhD, Co-founder of Meditope Biosciences and Associate Professor of Molecular Medicine at the Beckman Research Institute of the City of Hope, where he also serves as a member of the Developmental Cancer Therapeutics Program as well as Co-Director of the Drug Discovery and Structural Biology Core.  Dr. Williams' research centers on the application of structural and biophysical methods to understand the biological role of multivalency and energy additivity on multicomponent, macromolecular complexes and how to manipulate these properties to develop novel, highly specific antagonists.   Recently, his lab discovered the meditope binding site while investigating alternative masking agents for cetuximab. This discovery led to the founding of Meditope Biosciences.

About Meditope Biosciences, Inc. 
Meditope Biosciences is a biotechnology company developing best-in-class antibody-based cancer products.  Discovered at City of Hope, a National Cancer Institute designated Comprehensive Cancer Center, Meditope's technology is capable of turning any mAb into a proprietary, site-specific "Lego-like" system that is able to attach and detach drugs to antibodies without the need for chemical conjugation.  The result is a memAb (meditope-enabled mAb) product, which is anticipated to be significantly more effective and offer multiple manufacturing advantages compared to existing antibody-drug conjugate technologies.  The technology has the potential to advance the antibody market by producing an array of new therapeutic and diagnostic products.  More information regarding the company can be found by visiting www.meditope.com.


'/>"/>
SOURCE Meditope Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
2. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
3. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
4. Neurocrine Biosciences Reports First Quarter 2012 Results
5. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
7. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
8. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
9. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
10. Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences
11. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2017)...  The China and Canada joint tech ... water, energy and detergent, and features a powerful disinfection process. ... washing machine that washes and sanitizes women,s panties or babies, cloth ... ... does not require an external water inlet. ...
(Date:5/10/2017)... Mass., May 10, 2017 Hologic, Inc. (Nasdaq: ... results for the fiscal second quarter ended April 1, ... of $1.84 increased 666.7% compared to the prior year ... resulted in a significant gain, while non-GAAP diluted EPS ... 3.2%, or 3.8% in constant currency terms.  Excluding the ...
(Date:5/10/2017)... , May 10, 2017  The Corporate ... or employees of sleep therapy clinics to call ... sleep therapy clinic is involved in a substantial ... interested in hearing from an employee of a ... in a kickback scheme to provide medical practice groups ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... May 26, 2017 , ... Water damage to the flooring of several ... had left education officials with a number of critical issues to address before students ... to be accomplished with little or no disruption to class schedules. Second, the project ...
(Date:5/24/2017)... ... 24, 2017 , ... In modern research, success depends greatly ... for research and understanding the basic principles that were designed to drive that ... in stereo microscopy for brightfield and fluorescence typically used in laboratories working on ...
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... Altec ... its participation in nVerge 2017 – a one-day technology conference in San Diego, CA. ... management solution, which allows users to fully utilize and enhance their Sage ERP solutions ...
(Date:5/24/2017)... ... May 24, 2017 , ... Drs. Nicholas Rallis and ... now spent 10 years as clinical instructors for the reputable Full Mouth Rehabilitation ... Through the program, private practitioners receive cutting-edge clinical training and learn how to ...
(Date:5/24/2017)... OH (PRWEB) , ... May 24, 2017 , ... Patients ... in Cortland, OH, can now meet with Dr. Joseph Bedich for a consultation, with ... while simultaneously improving their oral health and functionality. , Dr. Bedich offers ...
Breaking Medicine News(10 mins):